CHIP-AML22:儿童初诊急性髓系白血病复杂临床试验
CHIP-AML22是一项在NOPHO-DB-SHIP联盟内开展的多国复杂临床试验,纳入18岁及以下初诊初治AML患者,主要目标是改善无事件生存。试验包括吉妥珠单抗奥唑米星随机化研究、FLT3-ITD+/NPM1wt患者quizartinib关联试验、基于MRD和遗传学的高危分层,以及标准风险患者巩固疗程随机非劣效研究,计划招募905例。
要点
- FLT3-ITD+/NPM1wt患者可入quizartinib关联试验评估安全性和疗效。
- CD33阳性患者随机接受两剂3 mg/m2吉妥珠单抗奥唑米星诱导治疗。
- 采用基于流式MRD和(细胞)遗传学的新标准识别高危患者。
核心结论
- CHIP-AML22采用基于风险的分层和靶向治疗,体现向更个性化治疗的转变。
- 除改善无事件生存外,研究旨在为减少所有患者毒性提供国际共识策略。
研究设计与样本
- CHIP-AML22是一项由Princess Máxima Center赞助的多国复杂临床试验,纳入18岁及以下初诊初治AML患者。
- 主方案计划招募905例患者,quizartinib关联试验计划招募60例患者。
- 研究包含吉妥珠单抗奥唑米星随机化研究、quizartinib关联试验、巩固疗程随机非劣效研究,并推荐所有患者使用右雷佐生。
关键数值与推荐
- FLT3-ITD+/NPM1wt患者可在诱导和巩固化疗期间及异基因造血干细胞移植后继续单药治疗中加用quizartinib。
- CD33阳性患者在诱导治疗期间随机接受两剂3 mg/m2吉妥珠单抗奥唑米星。
- 高危患者识别采用基于流式MRD和(细胞)遗传学的新标准。
- 标准风险患者随机比较两疗程与三疗程巩固治疗的无病生存非劣效性。
- 推荐所有患者使用心脏保护药物右雷佐生。
临床怎么用
- 试验设计允许未来引入新的治疗选择,为动态框架。
- 将进行中期分析以评估关联试验和随机化研究的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The overall survival of children with newly diagnosed acute myeloid leukemia (AML) in high-income countries has increased to 80% over the past decades. Nevertheless, a significant subset of patients experiences relapse and treatment is associated with both short- and long-term toxicities. The CHIP-AML22 protocol includes an updated standard-of-care treatment for children with AML within the NOPHO-DB-SHIP consortium. Targeted therapies are offered to specific subsets of patients and measures to reduce toxicity are being investigated. METHODS: CHIP-AML22 is a multinational complex clinical trial in newly diagnosed de novo AML patients up to and including 18 years of age, sponsored by the Princess Máxima Center. The primary aim is to improve event-free survival. To achieve this, (1) FLT3-ITD+/NPM1wt patients can participate in a linked-trial assessing safety and efficacy of quizartinib, in addition to conventional chemotherapy during induction and consolidation therapy and as continuation monotherapy after allogeneic hematopoietic stem cell transplantation; (2) a randomization study is incorporated on the use of two doses of 3 mg/m2 gemtuzumab ozogamicin during induction therapy in CD33-positive patients; and (3) updated criteria are used for the identification of high-risk patients, based both on flow measurable residual disease (MRD) and (cyto)genetic profiling. The design allows for introduction of new treatment options in the future. Furthermore, a randomization is included aiming to demonstrate non-inferiority in disease-free survival after two versus three consolidation courses in standard-risk patients. Additionally, the use of the cardioprotective drug dexrazoxane is recommended in all patients. Interim analyses will be conducted to assess safety and efficacy in the linked trial and randomization studies. Based on power calculations, we aim to recruit a total of 905 patients in the Master protocol and 60 patients in the linked Quizartinib trial. DISCUSSION: The risk-based approach and use of targeted therapies in CHIP-AML22 illustrate a shift toward more personalized treatment. Besides improving event-free survival, this study aims to contribute to the international consensus on strategies to reduce toxicity for all patients. The design of this study provides a dynamic framework, allowing for the potential introduction of emerging therapeutic options in the future. TRIAL REGISTRATION: CHIP-AML22 Master protocol: EU CT 2023-504999-25-00, Clinicaltrials.gov NCT05994690. Registered on 16-08-2023 Quizartinib linked-trial: EU CT 2023-505000-27-01, Clinicaltrials.gov NCT06262438. Registered on 16-02-2024.
引用
- Kaspers GJL, van Hamel M, Abrahamsson J, et al. CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium. Trials. 2026. PMID: 42321916. doi:10.1186/s13063-026-09855-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。